Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT02631408 |
Other study ID # |
iVRCT1_4 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 4
|
First received |
|
Last updated |
|
Start date |
August 2015 |
Est. completion date |
March 1, 2021 |
Study information
Verified date |
March 2021 |
Source |
Orthopedic Hospital Vienna Speising |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Vancomycin powder (for solution for Infusion) will be investigated (off-label usage) in
spinal fusion surgery. The powder will be locally administered into to the wound cavity
before wound closure.
Hypothesis: Locally applied vancomycin powder leads to a reduction in postoperative surgical
site infections
Description:
Vancomycin is being widely used as an antibiotic agent for intravenous and topical use. The
surgical application of vancomycin powder in Austria is limited as there is no powder with
marketing authorization for intraoperative, intrawound usage. Previous reports widely
document the application of vancomycin powder for solution for infusion. The powder is not
soluted, but instead directly spread throughout the wound surface. Limited data is available
for spinal fusion surgery, mostly retrospective studies. Results were promising, but the low
evidence level does not allow for a conclusion regarding routine usage. Additional
randomized, controlled trials are necessary to further investigate this matter.
This trial aims to investigate Vancomycin powder "Xellia" 1000mg, which has a Marketing
authorization, in an off-label usage (intrawound, intraoperatively) in spinal fusion surgery.
The investigational medicinal product will be used unmodified.